Soleno Therapeutics announces passing of former chairman Ernest Mario
Soleno Therapeutics (SLNO) announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age ...
Tenaya Therapeutics (TNYA) Receives a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report) today and set a price target ...
TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors
Trend International Holding disclosed a position in packaging and aerospace firm TriMas. Carlyle Group lowered its stake ...
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and ...
bovnews10d
Soleno Therapeutics Inc (SLNO) Stock: Surpassing Expectations in the Market?
On Thursday, Soleno Therapeutics Inc (SLNO) stock saw a decline, ending the day at $50.8 which represents a decrease of $-0.28 or -0.55% from the prior close of $51.08. The stock opened at $50.48 and ...
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Soleno Therapeutics shows promise with DCCR for reducing hyperphagia in PWS patients. Learn more about why SLNO stock is ...
Soleno Therapeutics Sees Unusually High Options Volume (NASDAQ:SLNO)
Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors purchased 11,478 put options on the company. This is an increase ...
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.
Soleno Therapeutics's Options Frenzy: What You Need to Know
Looking at options history for Soleno Therapeutics SLNO we detected 10 trades. If we consider the specifics of each trade, it ...
Soleno Therapeutics Jumps After FDA Says No Advisory Panel Meeting Needed for Prader-Willi Syndrome Drug
On Tuesday, the biopharmaceutical company said the U.S. Food and Drug Administration found no apparent need for an advisory committee meeting at this time for Soleno's application for DCCR, or ...